KIT and neoplasm: In the KIT‐T670I/BaF3‐ and GIST‐T1‐T670I‐inoculated mouse models, 100 mg·kg−1 nintedanib nearly completely suppressed tumour growth, with TGI values of 93.3% and 80.3%, respectively, while imatinib showed a limited effect on tumour growth at the same doses (Fig. 3B,C).